High-Definition Medicine

Torkamani, Ali; Andersen, Kristian G.; Steinhubl, Steven R.; Topol, Eric J.

doi:10.1016/j.cell.2017.08.007

Cited by 184 publications

(145 citation statements)

References 132 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…This example apparently corroborates the stance of the advocates of technology and digitalization [3] in modern medicine, as in the case of such a defect of the device, e.g. through damage of the electrodes, there is the risk that the defibrillator will falsely assume an indication of a shock for regularization of the cardiac activity.…”

Section: Both Legal Systems and Legal Subjects Essentiallysupporting

confidence: 55%

Telemetric Remote Monitoring Of Cardiac Devices. Is The Future Of Medicine A Liability Trap For The Physician.

Schneider¹,

Orru²

2018

Interventional Cardiology

View full text Add to dashboard Cite

Section: Both Legal Systems and Legal Subjects Essentiallysupporting

confidence: 55%

Telemetric Remote Monitoring Of Cardiac Devices. Is The Future Of Medicine A Liability Trap For The Physician.

Schneider¹,

Orru²

2018

Interventional Cardiology

View full text Add to dashboard Cite

“…Recent technological advances, such as in genomics, can facilitate the development of new medications by identifying and prioritizing drug targets, helping improve outcomes for established treatments (i.e., by patient stratification), and capturing in-depth treatment responses (e.g. biomarkers) to assist in evaluating efficacy [150, 151]. As such, it is a promising time to develop and evaluate new medications for OUD treatment.…”

Section: Future Directions For Medication Developmentmentioning

confidence: 99%

The Cholinergic System as a Treatment Target for Opioid Use Disorder

et al. 2018

View full text Add to dashboard Cite

Opioid overdoses recently became the leading cause of accidental death in the United States, marking an increase in the severity of the opioid use disorder (OUD) epidemic that is impacting global health. Current treatment protocols for OUD are limited to opioid medications, including methadone, buprenorphine and naltrexone. While these medications are effective in many cases, new treatments are required to more effectively address the rising societal and interpersonal costs associated with OUD. Here we review the opioid and cholinergic systems, and we examine the potential of acetylcholine (ACh) as a treatment target for OUD. The cholinergic system includes enzymes that synthesize and degrade ACh and receptors that mediate ACh’s effects. ACh is involved in many central nervous system functions that are critical to the development and maintenance of OUD, such as reward and cognition. Medications that target the cholinergic system have been approved for the treatment of Alzheimer’s disease, tobacco use disorder and nausea. Clinical and preclinical studies suggest that medications such as cholinesterase inhibitors and scopolamine, which target components of the cholinergic system, show promise for the treatment of OUD and further investigations are warranted.

show abstract

“…The driving principle behind precision medicine is that one size does not, in fact, fit all 15 . To date, the field has primarily focused on the use of patients' own genomic information to make personalized decisions about disease treatment 5 . During infectious disease outbreaks, however, genomic sequence information from the pathogen is arguably more important than an individual's genomic data for designing appropriate treatment and intervention strategies 16 .…”

Section: Precision Epidemiology In the Clinicmentioning

confidence: 99%